Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Consumer Staples Select Sector SPDR Fund — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Consumer Staples Select Sector SPDR Fund trades at $86.39 (market cap $14.15B). The key difference: Consumer Staples Select Sector SPDR Fund is far larger — about 14.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Consumer Staples Select Sector SPDR Fund for 73 Days on average.
| MRVI | XLP | |
|---|---|---|
Market Cap | $972.90M | $14.15B |
Volume | 4,325,710 | 10,004,762 |
Sector | Health | — |
52-Week High | $9.00 | $90.00 |
52-Week Low | $2.83 | $75.61 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
XLP trades at $84.19, down 0.26% on the day, with a bullish technical outlook supported by moving averages and ADX signals. Analyst consensus is unanimously positive with 100% buy ratings. Recent news highlights its competitive expense ratio and defensive appeal amid market volatility, with strong performance relative to discretionary sectors in 2026.
The ETF's low costs and sector resilience underpin a favorable outlook, though overbought RSI levels and interest rate sensitivity pose near-term risks. Institutional favor and dividend stability offer long-term value, but macroeconomic pressures require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
